KDA GROUP OPENS A U.S. SUBSIDIARY AND ACCELERATES THE GROWTH OF ITS MEDHERIZE SOLUTION
MWN-AI** Summary
KDA Group Inc. (TSXV: KDA), a leader in innovative healthcare solutions, has announced the opening of its U.S. subsidiary, set to commercialize its Medherize therapeutic monitoring platform in 2026. This move taps into a vast specialty drug market in the U.S. valued at over USD 243 billion, where specialty drugs currently represent around 40% of prescription revenues. As the market has expanded, driven by increasing at-home oral oncology treatments, the demand for effective management solutions like Medherize has surged.
Medherize is a SaaS platform designed to enhance therapeutic adherence and improve coordination among healthcare professionals while collecting real-world clinical data. Already implemented in key Canadian hospitals, it efficiently monitors complex oral cancer treatments and mitigates therapy discontinuations. KDA’s entry into the U.S. market represents a significant strategic leap, with plans to adapt Medherize to local healthcare frameworks and integrate with American laboratory systems, building on the successful Canadian integration with Dossier Santé Québec.
KDA's CEO, Marc Lemieux, emphasized that this initiative allows for a broader demonstration of KDA's technology and partnerships across North America, addressing a universal challenge in managing specialty oral treatments. With the U.S. market’s scale and growth potential, KDA aims to leverage its expertise in digital healthcare solutions to capture value in a rapidly evolving sector.
KDA Group Inc. continues to focus on technological innovations within the healthcare sphere, striving for high standards and recognized expertise among pharmaceutical and medical stakeholders. The subsidiary’s success may serve as a catalyst for future growth as KDA seeks to position itself as a frontrunner in transforming healthcare delivery systems.
MWN-AI** Analysis
KDA Group Inc. (TSXV: KDA) has made a significant strategic advance by opening its U.S. subsidiary, positioning itself to tap into the lucrative U.S. specialty drug market, projected to be valued at over USD 243 billion by 2023. This move not only marks KDA's direct participation in one of the world’s largest specialty drug markets, but also allows for the commercialization of its innovative Medherize therapeutic monitoring platform, specifically targeted at oncology treatments.
The trend towards at-home oral oncology treatments represents a rapidly growing sector within the healthcare market. With specialty drugs now accounting for nearly 40% of total prescription dispensing revenues in the U.S., KDA's Medherize addresses a critical need for enhanced patient management and adherence. This Software as a Service (SaaS) platform is already yielding positive outcomes in Canada and shows substantial potential to scale effectively within the American healthcare infrastructure.
As KDA prepares for its entry into the U.S. market in 2026, investors should consider the implications of this expansion. The U.S. market is not only larger but also more dynamic, with significant revenue generating opportunities facilitated by the rising costs associated with specialty drugs. KDA's ability to integrate its platform with U.S. laboratory systems and its focus on real-world clinical data collection positions it well against competitors in a fragmented market comprised of a few dominant players.
However, while the prospects are optimistic, potential investors should remain cautious. The healthcare technology landscape is often fraught with regulatory challenges and competitive pressures. Continuous monitoring of KDA's growth metrics post-expansion, alongside broader trends in the specialty drug market, will be essential. Overall, KDA presents a compelling growth story in the healthcare sector that investors may want to keep on their radar.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
THETFORD MINES, QC, Nov. 17, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the official opening of its U.S. subsidiary to launch, starting in 2026, the commercialization of Medherize, its therapeutic monitoring platform specialized in oncology. This strategic expansion positions KDA in one of the world's largest specialty drug markets, valued at more than USD 243 billion in 20231.
In the United States, specialty drugs now account for nearly 40% of total prescription dispensing revenues, up from 24% a decade ago and the specialty pharmacy segment is dominated by a few major players generating between USD 4.6 billion and 73 billion annually1. This market, several times larger than that of Canada, is experiencing sustained growth driven by the rise of at-home oral oncology treatments.
Oral specialty drugs, distributed through a network of community and specialty pharmacies, are among the most expensive therapeutic products in the world. The annual cost per patient can reach tens or even hundreds of thousands of dollars for certain targeted therapies or innovative treatments. The value-added opportunity for management and adherence solutions is therefore considerable. These drugs, essential for patients suffering from cancer, rare diseases, or severe chronic conditions, represent a major economic and clinical challenge for pharmaceutical companies and public payers alike.
Medherize directly addresses this need: a SaaS (Software as a Service) platform that improves therapeutic adherence, interprofessional coordination, and the collection of real-world clinical data. Already deployed at Centre hospitalier universitaire de Québec – Université Laval (CHU de Québec), Hôpital Saint-Sacrement, the solution has proven effective in monitoring complex oral treatments and reducing therapy discontinuations.
KDA's new U.S. subsidiary will allow Medherize to be adapted to local healthcare infrastructures, particularly through ongoing analysis and integration with American laboratory systems, building on the company's successful integration with Dossier Santé Québec (DSQ).
"Our direct presence in the United States marks a pivotal step in our international expansion," said Marc Lemieux, Chief Executive Officer and Chairman of the Board of KDA.
"Medherize addresses a universal challenge: the efficient management and monitoring of specialty oral treatments. The U.S. market is many times larger than ours, representing a major lever to showcase our technology and pharmaceutical partnerships across North America," added Mr. Lemieux.
ABOUT KDA GROUP
KDA Group is a leader in technological innovations and specialized software solutions (SaaS – Software as a Service) for the healthcare professionals' market. KDA is a corporation that offers high-quality products and has recognized and respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the healthcare's digital transformation, and are available for the Canadian and international markets. Additional information about the Corporation is available at www.groupkda.com and on SEDAR+ at www.sedarplus.ca.
REFERENCE
1- Specialty Pharmacy : The Trends Shaping Best Practices -
https://www.pharmaceuticalcommerce.com/view/specialty-pharmacy-trends-shaping-best-practices.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE KDA Group Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2025/17/c5144.html
FAQ**
How does KDA Group Inc. KDA:CC plan to tailor its Medherize platform to meet the specific needs of the U.S. healthcare system, and what potential partnerships are being pursued to enhance its market entry?
What strategies will KDA Group Inc. KDA:CC implement to compete against established players in the U.S. specialty drug market, which generates revenues between USD 4.6 billion and 73 billion annually?
Given the rising costs and complexity of oral specialty drugs, what metrics will KDA Group Inc. KDA:CC use to measure the success of Medherize in improving patient adherence and clinical outcomes once deployed in the U.S.?
In light of the forward-looking statements concerning market uncertainties, what are KDA Group Inc. KDA:CC's contingency plans to mitigate risks associated with their expansion into the U.S. oncology market?
**MWN-AI FAQ is based on asking OpenAI questions about Kda Group Inc. (TSXVC: KDA:CC).
NASDAQ: KDA:CC
KDA:CC Trading
-4.55% G/L:
$0.105 Last:
2,500 Volume:
$0.11 Open:
